S1 Episode 2: Frontline Therapy for Multiple ...

Joseph Mikhael, MD, and Ashley Rosko, MD, discuss the role of comorbidities in multiple myeloma and stress the importance of shifting away from the sole use of age-based treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape.com ( https://ww ...  Show more

Joseph Mikhael, MD, and Saad Usmani, MD, discuss options in managing triple-class refractory multiple myeloma including selinexor, belantamab mafodotin, and CAR T-cell therapy. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/vie ...  Show more

In this continuation of our myeloma series, we build on our prior discussion about myeloma pharmacology, this time discussing how to select the optimal regimen for treatment of our patients.

Co ...

Join experts Drs Kevin Kalinsky and Heather McArthur as they discuss the latest studies guiding their decisions when treating patients with TNBC in clinic. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/viewarticle/991253). The ...  Show more

In this episode, we start with a little bit of story time about the history of myeloma treatments and how we got to the present day. We then finish off the episode with how this information helped us treat transplant ineligible patients. ...

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a b ...  Show more